Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance
Open Access
- 1 January 2013
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 4, 392
Abstract
The increasing incidence and prevalence of multidrug resistance (MDR) among contemporary Gram-negative bacteria represents a significant threat to human health. Since their discovery, β-lactam antibiotics are a major component of the armamentarium against these serious pathogens. Unfortunately, a wide range of β-lactamase enzymes have emerged that are capable of inactivating these powerful drugs. In the past 30 years, a major advancement in the battle against microbes has been the development of β-lactamase inhibitors, which restore the efficacy of β-lactam antibiotics (e.g., ampicillin/sulbactam, amoxicillin/clavulanate, ticarcillin/clavulanate, and piperacillin/tazobactam). Unfortunately, many newly discovered β-lactamases are not inactivated by currently available inhibitors. Is there hope? For the first time in many years, we can anticipate the development and introduction into clinical practice of novel inhibitors. Although these inhibitors may still not be effective for all β-lactamases, their introduction is still welcome. This review focuses on the novel β-lactamase inhibitors that are closest to being introduced in the clinic.Keywords
This publication has 60 references indexed in Scilit:
- Identification and Characterization of the First Escherichia coli Strain Carrying NDM-1 Gene in ChinaPLOS ONE, 2013
- The Future of Antibiotics and ResistanceNew England Journal of Medicine, 2013
- Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitorProceedings of the National Academy of Sciences, 2012
- Carbapenems: Past, Present, and FutureAntimicrobial Agents and Chemotherapy, 2011
- In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumanniiJournal of Antimicrobial Chemotherapy, 2011
- Design, Synthesis, and Crystal Structures of 6-Alkylidene-2′-Substituted Penicillanic Acid Sulfones as Potent Inhibitors of Acinetobacter baumannii OXA-24 CarbapenemaseJournal of the American Chemical Society, 2010
- Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological studyThe Lancet Infectious Diseases, 2010
- The 10 × ‘20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020Clinical Infectious Diseases, 2010
- Inhibition of the Class C β-Lactamase from Acinetobacter spp.: Insights into Effective Inhibitor DesignBiochemistry, 2009
- Re‐examining the role of Lys67 in class C β‐lactamase catalysisProtein Science, 2009